We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Suffers U.S. Patent Loss for Childhood Asthma Drug
AstraZeneca Suffers U.S. Patent Loss for Childhood Asthma Drug
April 9, 2013
A U.S. patent protecting AstraZeneca’s (AZ) Pulmicort Respules was deemed invalid last week, opening the door for generic versions of the asthma drug to hit store shelves.